Sign In
Buy DGX
$233.72
+1.77 (+0.763%)
At Close: Aug 04, 2026
STERIS (STE) Q1 Earnings Match Estimates, EPS View Down
01:54pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.
Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up
04:14pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Henry Schein (HSIC) reports better-than-expected Q2 earnings with impressive sales growth across the Medical and Technology and Value-added Services segments.
DaVita (DVA) Beats on Q2 Earnings, Reiterates FY22 EPS View
03:39pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
DaVita (DVA) records an overall solid Q2 performance owing to strength in its Other segment's revenues and uptick in total U.S. dialysis treatments.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up
02:36pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
The contraction in Zimmer Biomet's (ZBH) gross margin is concerning.
IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down
02:25pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.
Avantor's (AVTR) Stock Falls 8.8% Since Q2 Earnings Miss
07:05am, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Avantor's (AVTR) robust performance across majority of its segments drives its Q2 sales, despite business challenges.
Teleflex's (TFX) Q2 Earnings Top Estimates, 2022 View Down
01:47pm, Monday, 01'st Aug 2022 Zacks Investment Research
For UroLift, Teleflex (TFX) witnesses revenue declines in all sites of service, including hospital, ASC and physician's office.
Chemed (CHE) Q2 Earnings Surpass Estimates, Margins Grow
05:57pm, Friday, 29'th Jul 2022 Zacks Investment Research
Chemed (CHE) reports better-than-expected earnings in the second quarter, with a robust performance by the Roto-Rooter segment driving the top line.
Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up
05:54pm, Friday, 29'th Jul 2022 Zacks Investment Research
Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
03:57pm, Friday, 29'th Jul 2022 Zacks Investment Research
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
03:28pm, Friday, 29'th Jul 2022 Zacks Investment Research
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
Integer Holdings (ITGR) Q2 Earnings Miss, FY22 View Revised
02:13pm, Friday, 29'th Jul 2022 Zacks Investment Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales besides strength in the majority of product lines.
LabCorp (LH) Q2 Earnings Top Estimates, Raises '22 EPS View
05:15pm, Thursday, 28'th Jul 2022 Zacks Investment Research
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.
Hologic (HOLX) Q3 Earnings Beat Estimates, Margins Down
05:14pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Hologic (HOLX) reports better-than-expected results in the fiscal third quarter with robust sales performance in the GYN Surgical business.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
04:50pm, Thursday, 28'th Jul 2022 Zacks Investment Research
QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
